tiprankstipranks
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Forecast & Price Target

582 Followers
See the Price Targets and Ratings of:

AVDL Analyst Ratings

Strong Buy
5Ratings
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Avadel
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVDL Stock 12 Months Forecast

Average Price Target

$22.80
▲(80.67% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Avadel Pharmaceuticals in the last 3 months. The average price target is $22.80 with a high forecast of $27.00 and a low forecast of $20.00. The average price target represents a 80.67% change from the last price of $12.62.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","28":"$28","12.25":"$12.25","17.5":"$17.5","22.75":"$22.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.8,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$22.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12.25,17.5,22.75,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Aug<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.69,15.636923076923077,16.583846153846153,17.53076923076923,18.47769230769231,19.424615384615386,20.371538461538464,21.318461538461538,22.265384615384615,23.212307692307693,24.159230769230767,25.106153846153845,26.053076923076922,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.69,15.313846153846153,15.937692307692307,16.56153846153846,17.185384615384613,17.80923076923077,18.433076923076925,19.056923076923077,19.68076923076923,20.304615384615385,20.92846153846154,21.552307692307693,22.176153846153845,{"y":22.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.69,15.098461538461539,15.506923076923076,15.915384615384616,16.323846153846155,16.732307692307693,17.14076923076923,17.549230769230768,17.95769230769231,18.366153846153846,18.774615384615384,19.183076923076925,19.591538461538462,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.47,"date":1677196800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.57,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.96,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.38,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.12,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.53,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.69,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$27.00Average Price Target$22.80Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co.
$17.00
Buy
34.71%
Upside
Reiterated
11/09/23
Strong 3Q23 Revenues and Robust Pipeline Bolster Buy Rating on Avadel Pharmaceuticals: An Analysis of Kaplan's Recommendation
Leerink Partners
$18.00
Buy
42.63%
Upside
Reiterated
11/08/23
Strong Sales and Positive Prospects: A Buy Rating Justified for Avadel Pharmaceuticals
Piper Sandler
$18.00
Buy
42.63%
Upside
Reiterated
08/10/23
Piper Sandler Sticks to Its Buy Rating for Avadel Pharmaceuticals (AVDL)
Jefferies
$12.00
Buy
-4.91%
Downside
Reiterated
03/30/23
Jefferies Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
LifeSci Capital
Buy
Reiterated
01/08/24
This morning, Avadel Pharmaceucals (Nasdaq : AVDL) announced ~$19M and ~$28M of preliminary net revenue from sales of Lumryz, their once-nighty sodium oxybate, for Q4 and FY 2023 respecvely, beang average consensus revenue esmates of $16M and $24M for the fourth quarter and full year 2023 respecvely. We look forward to the audited full results for the FY 2023 on or before February 29, 2024. We are encouraged to note that more than 1,000 paents have iniated therapy through December 31 st . Demand remains robust as more than 1,900 paents are enrolled in the RYZUP program, Avadel’s paent support services, up 900 paents from last quarter’s update. The majority were paents on a first generaon oxybate who switched to Lumryz, with some paents who had previously tried and disconnued a first generaon oxybate, and some paents who are new to oxybate.

Best Analysts Covering Avadel Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy AVDL and Sell After:
1 Month
Ami FadiaNeedham
Success Rate
12/22 ratings generated profit
55%
Average Return
+7.64%
reiterated a buy rating 2 months ago
Copying Ami Fadia's trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +7.64% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Ami FadiaNeedham
Success Rate
13/22 ratings generated profit
59%
Average Return
+13.12%
reiterated a buy rating 2 months ago
Copying Ami Fadia's trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +13.12% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Ami FadiaNeedham
Success Rate
15/22 ratings generated profit
68%
Average Return
+69.68%
reiterated a buy rating 2 months ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +69.68% per trade.
2 Years
Marc GoodmanLeerink Partners
Success Rate
16/17 ratings generated profit
94%
Average Return
+91.44%
reiterated a buy rating 4 months ago
Copying Marc Goodman's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +91.44% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVDL Analyst Recommendation Trends

Rating
Aug 23
Nov 23
Dec 23
Jan 24
Feb 24
Strong Buy
6
9
9
8
2
Buy
7
4
4
4
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
13
12
6
In the current month, AVDL has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVDL average Analyst price target in the past 3 months is $22.80.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AVDL Financial Forecast

AVDL Earnings Forecast

Next quarter’s earnings estimate for AVDL is -$0.28 with a range of -$0.32 to -$0.23. The previous quarter’s EPS was -$0.41. AVDL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.58% of the time in the same period. In the last calendar year AVDL has Underperformed its overall industry.
Next quarter’s earnings estimate for AVDL is -$0.28 with a range of -$0.32 to -$0.23. The previous quarter’s EPS was -$0.41. AVDL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.58% of the time in the same period. In the last calendar year AVDL has Underperformed its overall industry.

AVDL Sales Forecast

Next quarter’s sales forecast for AVDL is $18.19M with a range of $14.87M to $19.60M. The previous quarter’s sales results were $7.01M. AVDL beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.94% of the time in the same period. In the last calendar year AVDL has Outperformed its overall industry.
Next quarter’s sales forecast for AVDL is $18.19M with a range of $14.87M to $19.60M. The previous quarter’s sales results were $7.01M. AVDL beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.94% of the time in the same period. In the last calendar year AVDL has Outperformed its overall industry.

AVDL Stock Forecast FAQ

What is AVDL’s average 12-month price target, according to analysts?
Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is $22.80.
    What is AVDL’s upside potential, based on the analysts’ average price target?
    Avadel Pharmaceuticals has 80.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVDL a Buy, Sell or Hold?
          Avadel Pharmaceuticals has a conensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avadel Pharmaceuticals’s price target?
            The average price target for Avadel Pharmaceuticals is $22.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $27.00 ,the lowest forecast is $20.00. The average price target represents 80.67% Increase from the current price of $12.62.
              What do analysts say about Avadel Pharmaceuticals?
              Avadel Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of AVDL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis